Compare AUPH & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUPH | PBH |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2014 | 2004 |
| Metric | AUPH | PBH |
|---|---|---|
| Price | $16.29 | $52.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $17.25 | ★ $75.33 |
| AVG Volume (30 Days) | ★ 1.2M | 512.3K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | 0.53 | ★ 0.61 |
| Revenue | $283,055,000.00 | ★ $975,777,000.00 |
| Revenue This Year | $17.54 | N/A |
| Revenue Next Year | $15.74 | $4.31 |
| P/E Ratio | ★ $31.08 | $83.95 |
| Revenue Growth | 20.38 | ★ 36.77 |
| 52 Week Low | $10.34 | $42.62 |
| 52 Week High | $19.25 | $71.07 |
| Indicator | AUPH | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 53.30 |
| Support Level | $14.61 | $50.49 |
| Resistance Level | $16.46 | $55.99 |
| Average True Range (ATR) | 0.48 | 1.41 |
| MACD | 0.10 | -0.11 |
| Stochastic Oscillator | 50.68 | 46.44 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.